Patricia Richard

Director & Head of Research @Stellate Therapeutics

NY, US

Worked with CEO to supply and organize data for successful $5M+ seed funding of company + Designed, led, and managed in vitro and in vivo preclinical studies for neurological disorders including Parkinson’s and Alzheimer’s diseases + Designed and coordinated studies conducted by Contract Research Organizations and academic labs + Designed and supervised in-house lab experiments + Managed our research team of 2 Research Scientists, 1 Program Manager and 1 Bioinformatics intern + Advanced lead asset to IND-Enabling Studies and monitored further safety studies performed at CROs + Established new Parkinson’s disease program run virtually through collaboration with an AI-driven drug design company + Wrote and oversaw grant applications + Contributed to Stellate Therapeutics clinical strategy + Investigated indication expansion research for lead compound into Friedreich’s Ataxia and Phenylketonuria + Published data on the neuroprotective effect of our lead compound, a microbiome-derived molecule and mRNA translation modifier, in in vitro models of neurodegeneration PUBLICATION: •Richard P, Kozlowski L, Guillorit H, Garnier P, McKnight NC, Danchin A, Manière X (2021) Queuine, a bacterial-derived hypermodified nucleobase, shows protection in in vitro models of neurodegeneration. PLoS One.

Université Paul Sabatier Toulouse III

Doctor of Philosophy (PhD), Molecular Biology

Columbia University in the City of New York

Python programming

Columbia University in the City of New York

Introduction to Finance-Corporate Finance, Grade: A+

Université Paul Sabatier Toulouse III

Master's degree, Molecular, Cellular and Developmental Biology, Ranked first in program

Columbia University in the City of New York

Managing Human Behavior in the Organization, Grade: A